XML 86 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Accounts payable and accured liabilities
 12 Months Ended
Nov. 30, 2023
Trade and Accrued Payables [Abstract]  
Accounts payable and accured liabilities
15.
Accounts payable and accrued liabilities
                         
 
  
    
Note
 		       
2023
          
2022
  
 
  
       
Trade payables
            $ 6,990       $ 12,886  
       
Accrued liabilities and other payables
              15,016        18,951  
       
Salaries and benefits due to key management personnel
      28       1,036        3,387  
       
Employee salaries and benefits payable
              3,053        1,298  
       
Liability related to deferred stock unit plan
      20(e)       39        589  
       
Accrued interest payable on convertible unsecured senior notes and Loan Facility
      17 and 18        840        1,108  
       
TaiMed milestone (a)
      13       1,497        2,846  
 
  
       
             $ 28,471      $ 41,065  
 
  
 
  (a)
On October 3, 2022, the Company announced that the United States Food and Drug Administration approved Trogarzo
®
(ibalizumab-uiyk) for administration by intravenous (IV) push, a method by which the undiluted medication is “pushed” by syringe for faster administration into the body’s circulation. Under the TaiMed
A
greement, the Company ha
d
 additional contingent cash-based milestones based on the attainment of the above milestones. Accordingly
,
a $3,000 cash payment, payable in two annual
equal
installments of $
1,500
has been accrued. The second payment has been discounted to reflect the effective interest rate of the liability due in year
 
two
. The first installment of $ 1,500 was paid in 2023 and the second will be paid in 2024.